The Alabama to Zambia Clinical Trials Unit (A-to-Z CTU) represents a collaboration between the University of Alabama at Birmingham (UAB) and the Centre for Infectious Diseases Research in Zambia (CIDRZ). UAB has been continuously funded to perform NIH-funded HIV network clinical trials since 1990 and in 2015 added the CIDRZ CRS at the request of DAIDS. Over the past 6 years, our team has successfully enrolled over 1000 participants, including 45% female and 59% minority participants, into 48 network trials and contributed to over 175 publications of the networks. We have met or exceeded the expectations regarding enrollment, retention, data management, pharmacy management, and laboratory facilities and metrics. The past performance of the A-to-Z CTU exemplifies the preparedness of our team to contribute to the science of the NIH-funded HIV clinical trials networks for the next seven years. In this application, we highlight the A-to-Z CTU commitment to HIV research with the following specific aims:
Aim 1. Enroll and retain participants efficiently into HIV clinical trials at our two clinical research sites capable of yielding the highest quality data to meet the needs of the HVTN, the HPTN and the ACTG scientific networks and their respective scientific research agendas.
Aim 2. Maintain a cohesive, integrated group of investigators and staff where communication, community engagement, interaction, problem solving, flexible staffing, quality data and sample management, and regulatory assurance currently exist as evident via our track record of high-quality performance.
Aim 3. Contribute to the respective scientific agendas by remaining engaged with the network leadership to respond quickly to emerging scientific priorities, including the ability to rapidly scale-up a protocol- specific site for targeted, high-priority studies for any DAIDS-funded research network.
Aim 4. Mentor a talented group of young investigators who will lay the foundation for continued excellence in this ever-changing field of HIV research domestically and internationally. We will leverage our long-standing experience in clinical trials to contribute to HIV research through the NIH- funded HIV clinical trial networks.

Public Health Relevance

The Alabama to Zambia Clinical Trials Unit (A-to-Z CTU) is dedicated to advancing science to improve the quality and longevity of lives of people living with HIV (PLWH), ending the HIV epidemic, and eliminating disparities for PLWH. Our two Clinical Research Sites are geographically located in Alabama, where the US HIV epidemic is ongoing, and Zambia, where the global burden of HIV is greatest. Our integrated leadership group and staff will leverage our long-standing experience in clinical trials to contribute to the global efforts to end the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069452-15
Application #
10055036
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Pouliot, Eileen M
Project Start
2007-02-01
Project End
2027-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
15
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Salantes, D Brenda; Zheng, Yu; Mampe, Felicity et al. (2018) HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest 128:3102-3115
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Tassiopoulos, Katherine; Abdo, Mona; Wu, Kunling et al. (2017) Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS 31:2287-2294
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Robbins, Gregory K; Cohn, Susan E; Harrison, Linda J et al. (2016) Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. HIV Clin Trials 17:165-72
Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7

Showing the most recent 10 out of 72 publications